What We're Reading: Page 387
Industry reads hand-picked by our editors
Nov 19, 2014
-
Becker's Hospital Review
HHS scraps regulations for 340B drug pricing program
-
-
Docs breathe sigh of relief as Actavis buyout ends Valeant-Allergan drama
-
-
Merck dances: Keytruda more than doubles PFS in some melanoma patients
-
-
How pharma has improved patients' access to drugs since 2012
-
-
FDA commish to talk drug safety at China regulatory chief confab
-
Nov 18, 2014
-
-
Cancer immunotherapy specialist Juno Therapeutics files for IPO
-
UPDATED: Actavis buys Allergan for $66 billion
-
-
-
Finally: FDA reverses course, OKs Sanofi's Lemtrada for MS
-
Another big win for Roche as Avastin nabs FDA ovarian cancer indication
-
-
-
EU's top drug regulator forced out by EMA panel
Nov 17, 2014
-
AstraZeneca in preclinical development for Brilinta reversal agent
-
-
Apollo Global Manangement joins bidding wars for GSK's mature drugs
-
-
FDA approves new Invega indication for schizoaffective disorder
-
-
Pfizer, Gates Foundation team up to get injectable contraceptives to poor countries
-
-
FDA has concerns over bioequivalence of two Concerta generics
-
Japanese transparency data raises eyebrows about pharma spending
Nov 14, 2014
-
-
Let's make a deal: Allergan, Actavis talk $60 billion merger
-
-
Gilead, AbbVie hep C drugs score 97% cure rates, Regulus gets cold shoulder
-
-
Activist investor Bill Ackman's $2 billion fallback plan for Valeant
-
Indian pharma really feeling the pain of lagging US generic approvals
-
GSK applying for expanded Revolade indication in the EU
-
No more half measures: Senate to add Ebola to priority review program
-
Advaxis wants to investigate a compound for head & neck HPV-related cancers
Nov 13, 2014
-
10 major hospitals ask Congress to scrutinize Genentech distribution changes
-
-
Shire CEO: The future looks bright—who needs AbbVie?
-
-
-
Activist investor Bill Ackman's $2 billion fallback plan for Valeant
-
-
Does a common 'algae virus' found in humans really make them dumb?
-
GE Healthcare and Takeda to take on liver disease R&D together
-
Nov 12, 2014
-
Specter of antitrust charges looms as Justice Department probes generic price hikes
-
-
Swing and a miss: Merck's ambitious 4-week hep C regimen fails
-
-
Amgen gets PDUFA date for hotly anticipated PCSK9 anti-cholesterol drug
-
-
Pfizer: Nothing shady about our relationship with Missouri Attorney General
-
Cigna responds to discrimination claims with cheaper HIV meds in Florida
-
-
Best of BD: Is the current antibiotic pipeline really that bad? [INFOGRAPHIC]
Nov 11, 2014
-
The cost of a cure: $188B to treat all US hep C patients with pricey new drugs
-
-
Advocates slam protracted UK negotiations over Novartis meningitis B vaccine
-
Salix Pharmaceuticals' inventory woes ruined potential Allergan buyout
-
Political unrest in Russia nixes deal with German pharma company
-
-
-
-
Isis Pharma wins $10M neurodegeneration treatment milestone from Biogen
-
Previous
